DANUTA HERZYK, Ph.D.
Program Development; Immunology & Oncology Therapeutic Area Leader
Department of Safety Assessment & Laboratory Animal Resources (SALAR)
Dr. Danuta Herzyk earned her MS degree in Pharmaceutical Sciences and Ph.D. in Clinical Immunology and Biochemistry from the Medical University of Wroclaw, Poland. She was a postdoctoral fellow at the Ohio State University (with Dr. Richard Mortensen in the Department of Microbiology and Immunology from 1985-1986 and with Dr. Mark Wewers in the Department of Pulmonary and Critical Care Medicine from 1987-1991). Dr. Herzyk joined the Department of Safety Assessment at GlaxoSmithKline R&D in 1992 and overtime became a Director of Immunologic Toxicology Laboratory. Her work involved mainly immunotoxicology testing of immunomodulatory biopharmaceuticals.
In 2007, Dr. Herzyk took a position of Senior Scientific Director in the Department of Safety Assessment at Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., USA. Her work continued in the development and non-clinical safety assessment of biopharmaceuticals and vaccines. In 2013 her role has been transitioned to the Immunology and Oncology Therapeutic Area Leader, in which she provides guidance and support to drug development teams.
Dr. Herzyk is author/co-author of over 50 peer-reviewed articles and book chapters, and co-editor of two books, "Immunotoxicology Strategies for Pharmaceutical Safety Assessment" (2008) and “Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics” (2013). She serves on the Editorial Board of Journal of Immunotoxicology and is an active member of Immunotoxicology Specialty Section (ITSS) and BioTechnology Specialty Section (BTSS) of the Society of Toxicology.